

Date: April 2, 2018

To, BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 Ref: Company Scrip Code: 532834	To, The Manager, Listing Department, National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Ref: Symbol: CAMLINFINE Series: EQ
---	--

Sub: Disclosure of events or information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, please note that the Company has entered into an joint venture agreement with Pahang Pharma (S) Pte Ltd., a company duly incorporated under the laws of Singapore. The disclosure related to the proposed joint-venture is as follows:

- a) **name of the party(ies) with whom the agreement is entered:** Pahang Pharma (S) Pte Ltd, a company organized under the Laws of Singapore and having its office at 20 Maxwell Road, #09-17 Maxwell House, Singapore.
- b) **Purpose of entering into agreement:** For incorporating a company in Singapore who shall be holding company for its subsidiary(ies) which shall be incorporated in ASEAN countries as per the business model basically to engage in research, development, production, trade and dealing in animal feed ingredients and animal feed nutrition products viz. Antioxidants, binders, acidifiers, stabilizers, disinfectants etc.
- c) **Shareholding, if any, in the entity with whom the agreement is executed:** Nil
- d) **Special terms of the agreement (In brief), special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any capital structure etc.:** The Company has the right to appoint two directors and Pahang Pharma (S) Pte. Ltd. has right to appoint one director in the holding company. The Company shall receive royalty at certain percentage of net-sales value as per the terms of the joint-venture contract.
- e) **whether the said party(ies) are related to promoter/ promoter group/ group companies in any manner? If yes, nature relationship:** No, the party is not related to the promoter/promoter group/group companies.
- f) **whether the transaction would fall within related party transaction(s) ? If yes, whether the same is done at "arms length":** The transaction does not fall within related party transactions.



- g) In case issuance of shares to the party(ies), details of issue price, class of shares issued: Not applicable as no shares are being issued to the party.
- h) Any other disclosures related to such agreements viz. the details of the nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc. : There shall be no nominee of Pahang Pharma (S) Pte. Ltd. on the board of directors of the Company. The proposed term of the joint venture is 30 years with investment in holding company in the proportion of 51% by the Company and 49% by Pahang Pharma (S) Pte. Ltd.

Kindly take the above information on records.

Thanking You,

For **Camlin Fine Sciences Limited**



Rahul Sawale
Group Company Secretary

